Cargando…

Sex-specific disease outcomes of HIV-positive and HIV-negative drug users admitted to an opioid substitution therapy program in Spain: a cohort study

BACKGROUND: Opioid substitution therapy has improved the survival of heroin users with and without HIV infection. We aimed to analyze sex differences in mortality rates and predictors of death among those admitted to a methadone treatment program (MTP). METHODS: Longitudinal study of patients enroll...

Descripción completa

Detalles Bibliográficos
Autores principales: Muga, Roberto, Rivas, Inmaculada, Faure, Eva, Fuster, Daniel, Zuluaga, Paola, Rubio, Manuela, Muñoz, Trinidad, Torrens, Marta, Tor, Jordi, Sanvisens, Arantza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4261781/
https://www.ncbi.nlm.nih.gov/pubmed/25231321
http://dx.doi.org/10.1186/1471-2334-14-504
_version_ 1782348327282540544
author Muga, Roberto
Rivas, Inmaculada
Faure, Eva
Fuster, Daniel
Zuluaga, Paola
Rubio, Manuela
Muñoz, Trinidad
Torrens, Marta
Tor, Jordi
Sanvisens, Arantza
author_facet Muga, Roberto
Rivas, Inmaculada
Faure, Eva
Fuster, Daniel
Zuluaga, Paola
Rubio, Manuela
Muñoz, Trinidad
Torrens, Marta
Tor, Jordi
Sanvisens, Arantza
author_sort Muga, Roberto
collection PubMed
description BACKGROUND: Opioid substitution therapy has improved the survival of heroin users with and without HIV infection. We aimed to analyze sex differences in mortality rates and predictors of death among those admitted to a methadone treatment program (MTP). METHODS: Longitudinal study of patients enrolled in a MTP from 1992 to 2010. Socio-demographic and drug use characteristics, and markers of viral infections were assessed at entry. Vital status was ascertained by clinical charts and the mortality register. Four calendar periods were defined according to the introduction of preventive and treatment interventions in Spain. Predictors of death were analyzed by Cox regression models. RESULTS: 1,678 patients (82.8% men) were included; age at first heroin use was 18.6 years (IQR: 16–23 years), and age at first entry into a MTP was 30.7 years (IQR: 26–36 years). A total of 441 (26.3%) deaths occurred during 15,124 person-years (p-y) of follow-up (median: 9.2 years, IQR: 4–13 years). HIV infection was the main predictor of death in men (HR = 3.5, 95% CI: 2.1-5.7) and women (HR = 3.2, 95% CI: 1.2-8.7 ) and main cause of death was HIV/AIDS. Overall mortality rate was 2.9 per 100 p-y (95% CI: 2.7-3.2 per 100 p-y) and death rates decreased over time: 7.4 per 100 p-y (95% CI: 6.3-8.8 per 100 p-y) for the 1992–1996 period to 1.9 per 100 p-y (95% CI: 1.6-2.4 per 100 p-y) for the 2007–2010 period. In women, a slightly increase in mortality was observed in recent periods specifically among HIV-positive women (3.7 per 100 p-y in period 2002–2006 and 4.5 per 100 p-y in 2007–2010). CONCLUSIONS: Significant reductions in mortality of patients in MTP are observed after nineteen years of observation. However, HIV infection shows a great impact on survival, particularly among HIV-infected women. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/1471-2334-14-504) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4261781
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-42617812014-12-10 Sex-specific disease outcomes of HIV-positive and HIV-negative drug users admitted to an opioid substitution therapy program in Spain: a cohort study Muga, Roberto Rivas, Inmaculada Faure, Eva Fuster, Daniel Zuluaga, Paola Rubio, Manuela Muñoz, Trinidad Torrens, Marta Tor, Jordi Sanvisens, Arantza BMC Infect Dis Research Article BACKGROUND: Opioid substitution therapy has improved the survival of heroin users with and without HIV infection. We aimed to analyze sex differences in mortality rates and predictors of death among those admitted to a methadone treatment program (MTP). METHODS: Longitudinal study of patients enrolled in a MTP from 1992 to 2010. Socio-demographic and drug use characteristics, and markers of viral infections were assessed at entry. Vital status was ascertained by clinical charts and the mortality register. Four calendar periods were defined according to the introduction of preventive and treatment interventions in Spain. Predictors of death were analyzed by Cox regression models. RESULTS: 1,678 patients (82.8% men) were included; age at first heroin use was 18.6 years (IQR: 16–23 years), and age at first entry into a MTP was 30.7 years (IQR: 26–36 years). A total of 441 (26.3%) deaths occurred during 15,124 person-years (p-y) of follow-up (median: 9.2 years, IQR: 4–13 years). HIV infection was the main predictor of death in men (HR = 3.5, 95% CI: 2.1-5.7) and women (HR = 3.2, 95% CI: 1.2-8.7 ) and main cause of death was HIV/AIDS. Overall mortality rate was 2.9 per 100 p-y (95% CI: 2.7-3.2 per 100 p-y) and death rates decreased over time: 7.4 per 100 p-y (95% CI: 6.3-8.8 per 100 p-y) for the 1992–1996 period to 1.9 per 100 p-y (95% CI: 1.6-2.4 per 100 p-y) for the 2007–2010 period. In women, a slightly increase in mortality was observed in recent periods specifically among HIV-positive women (3.7 per 100 p-y in period 2002–2006 and 4.5 per 100 p-y in 2007–2010). CONCLUSIONS: Significant reductions in mortality of patients in MTP are observed after nineteen years of observation. However, HIV infection shows a great impact on survival, particularly among HIV-infected women. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/1471-2334-14-504) contains supplementary material, which is available to authorized users. BioMed Central 2014-09-17 /pmc/articles/PMC4261781/ /pubmed/25231321 http://dx.doi.org/10.1186/1471-2334-14-504 Text en © Muga et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Muga, Roberto
Rivas, Inmaculada
Faure, Eva
Fuster, Daniel
Zuluaga, Paola
Rubio, Manuela
Muñoz, Trinidad
Torrens, Marta
Tor, Jordi
Sanvisens, Arantza
Sex-specific disease outcomes of HIV-positive and HIV-negative drug users admitted to an opioid substitution therapy program in Spain: a cohort study
title Sex-specific disease outcomes of HIV-positive and HIV-negative drug users admitted to an opioid substitution therapy program in Spain: a cohort study
title_full Sex-specific disease outcomes of HIV-positive and HIV-negative drug users admitted to an opioid substitution therapy program in Spain: a cohort study
title_fullStr Sex-specific disease outcomes of HIV-positive and HIV-negative drug users admitted to an opioid substitution therapy program in Spain: a cohort study
title_full_unstemmed Sex-specific disease outcomes of HIV-positive and HIV-negative drug users admitted to an opioid substitution therapy program in Spain: a cohort study
title_short Sex-specific disease outcomes of HIV-positive and HIV-negative drug users admitted to an opioid substitution therapy program in Spain: a cohort study
title_sort sex-specific disease outcomes of hiv-positive and hiv-negative drug users admitted to an opioid substitution therapy program in spain: a cohort study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4261781/
https://www.ncbi.nlm.nih.gov/pubmed/25231321
http://dx.doi.org/10.1186/1471-2334-14-504
work_keys_str_mv AT mugaroberto sexspecificdiseaseoutcomesofhivpositiveandhivnegativedrugusersadmittedtoanopioidsubstitutiontherapyprograminspainacohortstudy
AT rivasinmaculada sexspecificdiseaseoutcomesofhivpositiveandhivnegativedrugusersadmittedtoanopioidsubstitutiontherapyprograminspainacohortstudy
AT faureeva sexspecificdiseaseoutcomesofhivpositiveandhivnegativedrugusersadmittedtoanopioidsubstitutiontherapyprograminspainacohortstudy
AT fusterdaniel sexspecificdiseaseoutcomesofhivpositiveandhivnegativedrugusersadmittedtoanopioidsubstitutiontherapyprograminspainacohortstudy
AT zuluagapaola sexspecificdiseaseoutcomesofhivpositiveandhivnegativedrugusersadmittedtoanopioidsubstitutiontherapyprograminspainacohortstudy
AT rubiomanuela sexspecificdiseaseoutcomesofhivpositiveandhivnegativedrugusersadmittedtoanopioidsubstitutiontherapyprograminspainacohortstudy
AT munoztrinidad sexspecificdiseaseoutcomesofhivpositiveandhivnegativedrugusersadmittedtoanopioidsubstitutiontherapyprograminspainacohortstudy
AT torrensmarta sexspecificdiseaseoutcomesofhivpositiveandhivnegativedrugusersadmittedtoanopioidsubstitutiontherapyprograminspainacohortstudy
AT torjordi sexspecificdiseaseoutcomesofhivpositiveandhivnegativedrugusersadmittedtoanopioidsubstitutiontherapyprograminspainacohortstudy
AT sanvisensarantza sexspecificdiseaseoutcomesofhivpositiveandhivnegativedrugusersadmittedtoanopioidsubstitutiontherapyprograminspainacohortstudy